Nab-paclitaxel (Abraxane®)
Nab-paclitaxel (Abraxane®) in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinomoa of the pancreas.
Rapid Review
| Commenced | Completed | Outcome |
| 23/01/2014 | 02/03/2014 | Full Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 23/05/2014 | 05/09/2014 | Reimbursement not recommended |
The NCPE do not recommend reimbursement of nab-paclitaxel (Abraxane®).
December 2015
The HSE has approved reimbursement following confidential price negotiations.